NEW YORK (GenomeWeb) – Seattle-based NanoString Technologies announced today that health insurer Cigna has issued a positive coverage decision for the Prosigna Breast Cancer Gene Signature Assay.

The decision provides Cigna's approximately 13 million members with access to the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.